Mr Seppo Mäkinen France

Merieux Developement SA
LinkedIn logo Advisor 

Mr Pasi Markkanen

KYS Invest Ltd is an investor operating in pre-seed or seed phase of health or welfare companies We have been operating in Eastern-Finland since 1995. The company is owned by City of Kuopio, Northern-Savo Health District and Itä-Suomen rahasto (Fund of Eastern-Finland).

Business Type
KYS Invest

Mr Iacob Mathiesen Norway

Otivio is a Medtech company with technology which improves blood flow to the limbs of patients. This can be used for treatment of chronic ischemic wounds, in particular for patients with reduced peripheral circulation.

Another application is to exploit the improved blood flow to heat or cool patients by using the the limb as a heat exchanger.

Otivio is a coordinator of an EU funded project and are currently looking for funding to strenghten its organization and fund additional activites.

Otivio

Mr Mads Emil Matthiesen

Business Type
WiMed

Mr Markus Merne Finland

Company specialized in wireless and mobile solutions for monitoring, alarn and control wiithin health care and security markets.

We focus on eldercare and we already have thousands of users and have entered the growth phase. Major distribution deals have been signed in UK, NL, FR, SE, FI and will shortly be in US.

Looking to raise a total of 3 M in funding for the expansion and rapid growth.

Our leading product is the Vega GPS global solution with the wearable watch providing answers to 3 major challenges:

- protection always available

- always know where a person/wearer is

- interact with the users

Everon
LinkedIn logo CEO 

Mr Jari Mieskonen Finland

Business Type
Conor Venture Partners Oy
Managing Partner 

Dr Søren Møller Denmark

Novo Seeds is a life science supporting program launched by the Novo Nordisk Foundation and Novo A/S. Novo Seeds has two components, a pre-seed funding capacity and a seed financing fund. Both aim at identifying and developing the unexplored commercial potential present in academic and early stage applied research projects at universities and biotech companies within life science in Scandinavia.

The pre-seed program supports early stage projects based on ideas and results with commercial potential. Funding is given as grants in the same manner as other grants awarded by the Novo Nordisk Foundation.

The seed fund aims at supporting more advanced projects and will operate on commercial terms, i.e. support is given to projects and companies in exchange for ownership or other rights to the companies/projects. Typically, the seed program will invest in newly formed companies that are too early in their development stage to be supported by Novo A/S’ venture capital or other international investors

Website:
www.novo.dk
Business Type
Novo Seeds
Managing Investment Director 

Hartvig Munthe Kaas

Leverandorer for Helse Norge

Kathrine Myhre

Oslo Medtech